Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,404 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tissue specimen Clear all

Conditions: Fragile X Syndrome
Interventions: Not listed
Lead sponsor: Esoterix Genetic Laboratories, LLC; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Westborough, Massachusetts

Conditions: Non Small Cell Lung Carcinoma
Interventions: AZD6244, Erlotinib, AZD6244 + Erlotinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Davis, California • Los Angeles, California • South Pasadena, California + 2 more

Conditions: Pathological Processes in the Posterior Fossa, Dura Defects
Interventions: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care; Biological · Procedure
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 3 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 12
States / cities: Duarte, California • Sacramento, California • San Diego, California + 9 more

Conditions: Brown Adipose Tissue, Body Composition
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 14 Days to 28 Days
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hair Disease
Interventions: Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells, Stem/Stromal Cellular Isolation (Digestive), MatriStem Matrix (ACell) - Current Standard of Care, HD-PRP (High Density Platelet Rich Plasma), Emulsified AD-tSVF, Emulsified AD-cSVF; Procedure
Lead sponsor: Healeon Medical Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Irvine, California

Conditions: Infertility, Male, Cancer, Autoimmune Disorder
Interventions: Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Neoplasms, Breast Diseases
Interventions: OSNA Breast Cancer System; Device
Lead sponsor: Sysmex America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Santa Monica, California • Marietta, Georgia • St Louis, Missouri + 8 more

Conditions: Sarcoma
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Radiation · Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: Male only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Blood Loss, Surgical, Postoperative Hemorrhage
Interventions: Wearable optical hemodynamic monitoring device; Device
Lead sponsor: Hemorai Inc; Industry
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Sunscreening Agents
Interventions: BAY987521, Control; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Esophageal Cancer
Interventions: Cryotherapy; Device
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypoxia
Interventions: Vasoconstrictor Agents, Head/neck repositioning, Increase ETCO2, IV fluid bolus, Additional anesthesia, RBC transfusion, Increase FiO2; Drug · Other · Biological
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer, Immune-related Adverse Event
Interventions: Medical chart review; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulp Disease, Dental
Interventions: GentleWave®, EdgePRO™, Fotona LightWalker®, Conventional Needle Irrigation; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematoma
Interventions: CEUS or Contrast enhanced Ultrasound; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions: Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 100 Years
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Traumatic Amputation of Arm, Traumatic Amputation of Hand
Interventions: upper extremity/ hand transplantation; Procedure
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Springfield, Illinois

Conditions: Subarachnoid Hemorrhage, Anxiety, Pain, Delirium, Sleep
Interventions: Massage; Other
Lead sponsor: Sara E. Hocker, M.D; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: enoxaparin, heparin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Missing Tooth
Interventions: Minimally Traumatic Tooth Extraction, Immediate Implant Placement, Bone Graft Placement, Membrane placement, Collagen plug placement, Medications; Procedure · Device · Biological + 1 more
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Mastectomy
Interventions: Standard of care reconstruction, Surgery, Breast Mold; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Surgical Wound
Interventions: Nasalis Sling Flap, Lobed Transposition Flap; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 19 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Fibrin Sealant for the Sealing of Dura Sutures

Measurement of Body Fat in Infants

AGA Biocellular Stem/Stromal Hair Regenerative Study

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer

Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Study of the Hemorai Vysio Wearable Device for Monitoring Changes Related to Blood Loss in Patients During and After Surgery.

Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Cryotherapy for Locally Advanced Esophageal Cancer

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

Clinical Outcomes of Root Canal Treatment Using Modern Irrigation Protocols

Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas

Imaging of Brain Amyloid Plaques in the Aging Population

Vascularized Composite Allotransplantation of the Hand and Upper Extremity (Hand Transplant)

Massage Technique for Pain, Anxiety and Delirium in SAH Patients

Heparin or Enoxaparin in Patients With Cancer

Guided Bone Regeneration Around Immediate Implants

Interactive Design of Patient-Specific Molds for Tissue Shaping

Reconstruction Flaps for Nasal Surgical Wounds RCT